The global pyrogen and endotoxin testing market size was estimated at USD 2.56 billion in 2025 and is projected to reach USD 4.46 billion by 2033, growing at CAGR of 7.22% from 2026 to 2033. The increasing demand for pyrogen and endotoxin testing products in the pharmaceutical and biotechnology industries is a significant driver of market growth.
The rapid expansion of these industries, coupled with the rising number of new therapeutic launches, is expected to propel the demand for pyrogen and endotoxin testing products further. This growth highlights the critical role of pyrogen and endotoxin testing in ensuring the safety and efficacy of pharmaceutical and biotechnological products.
Several regulatory bodies and governments are taking various initiatives to train and create awareness about pyrogen and endotoxin testing. Government initiatives worldwide are pivotal in accelerating this transition. In June 2024, the 179th session of the European Pharmacopoeia (Ph. Eur.) Commission marked a significant advancement for animal welfare and contemporary pyrogen and endotoxin testing practices. During this session, the Commission approved the removal of the Rabbit Pyrogen Test (RPT) from 57 revised texts and introduced a comprehensive new general chapter on Pyrogenicity. This decision effectively abolished the RPT requirement across all Ph. Eur. texts, solidifying the transition toward in vitro testing methodologies, such as the Monocyte Activation Test (MAT).
The scope of the pyrogen and endotoxin testing industry is expanding significantly as technological advancements improve testing sensitivity, accuracy, and compliance with evolving regulatory standards. Increasing emphasis on ensuring the safety of pharmaceuticals, biologics, vaccines, and medical devices has driven the demand for advanced testing platforms capable of detecting both endotoxin and non-endotoxin pyrogens. The industry is gradually transitioning from traditional animal-based methods toward modern in vitro technologies that offer faster turnaround times and improved reproducibility. For instance, in May 2025, Minerva Biolabs GmbH introduced the NAT-MAT system, a next-generation pyrogen-detection platform that integrates the Monocyte Activation Test (MAT) with digital PCR. The system measures cytokine gene expression, including IL-1β and TNF-α, enabling more sensitive and rapid detection compared to conventional ELISA-based MAT assays. Such innovations highlight the expanding scope of advanced molecular and cell-based diagnostic technologies within pharmaceutical quality control processes.
In January 2026, BETMAT Biotechnology launched high-performance sustainable endotoxin testing services designed to meet evolving quality control requirements in pharmaceutical and medical device manufacturing. The new service focuses on providing reliable bacterial endotoxin testing (BET) solutions that comply with international pharmacopeial standards while supporting sustainability initiatives in laboratory testing. The service launch reflects the growing demand for efficient, standardized, and environmentally responsible endotoxin-detection technologies in pharmaceutical manufacturing. BETMAT’s testing infrastructure incorporates advanced automated instrumentation and strict quality management systems aligned with global pharmacopeial requirements, including USP, EP, BP, and ChP, ensuring traceable and reliable results.
Furthermore, the development of integrated testing platforms is strengthening the role of automated, standardized pyrogen-detection solutions across pharmaceutical manufacturing workflows. The NAT-MAT platform includes ready-to-use macrophage cells, nucleic acid extraction kits, and a triplex digital PCR assay, enabling reliable and automated testing for both quality control and in-process monitoring. These developments reflect the growing shift toward comprehensive testing systems that can improve efficiency and reduce manual laboratory procedures.
In addition, the ability of such technologies to support complete pyrogen and endotoxin testing creates opportunities to gradually replace traditional animal-based methods, such as the Rabbit Pyrogen Test. As regulatory agencies and industry stakeholders increasingly promote animal-free testing approaches, the adoption of advanced in vitro pyrogen detection technologies is expected to expand, thereby broadening the market scope and encouraging continued innovation in endotoxin and pyrogen and endotoxin testing solutions.
Increasing investment in R&D by the government and manufacturing companies for product development is one of the major factors contributing to the market's growth. New product development and launch is a key strategy adopted by manufacturers to maintain their dominance and to get maximum revenue share in the sector. As stated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2023, the research-based pharmaceutical industry invested around USD 48.65 billion in R&D in Europe in 2022. Hence, the need for pyrogen and endotoxin testing products is anticipated to upsurge during the forecast period.
Furthermore, the pyrogen and endotoxin testing industry is driven by the increasing demand for therapeutic drugs. Several companies are actively involved in developing new drug therapies. For instance, in 2023, the FDA approved 55 new drugs. Pyrogen testing in drug development assesses the presence or absence of pyrogens in parenteral pharmaceutical products. Moreover, the sterility of any drug does not indicate that it is pyrogen-free. Therefore, drugs that are expected to be sterile must be tested for the presence of pyrogens to control febrile reactions in patients.
This product will be delivered within 1-3 business days.
The rapid expansion of these industries, coupled with the rising number of new therapeutic launches, is expected to propel the demand for pyrogen and endotoxin testing products further. This growth highlights the critical role of pyrogen and endotoxin testing in ensuring the safety and efficacy of pharmaceutical and biotechnological products.
Several regulatory bodies and governments are taking various initiatives to train and create awareness about pyrogen and endotoxin testing. Government initiatives worldwide are pivotal in accelerating this transition. In June 2024, the 179th session of the European Pharmacopoeia (Ph. Eur.) Commission marked a significant advancement for animal welfare and contemporary pyrogen and endotoxin testing practices. During this session, the Commission approved the removal of the Rabbit Pyrogen Test (RPT) from 57 revised texts and introduced a comprehensive new general chapter on Pyrogenicity. This decision effectively abolished the RPT requirement across all Ph. Eur. texts, solidifying the transition toward in vitro testing methodologies, such as the Monocyte Activation Test (MAT).
The scope of the pyrogen and endotoxin testing industry is expanding significantly as technological advancements improve testing sensitivity, accuracy, and compliance with evolving regulatory standards. Increasing emphasis on ensuring the safety of pharmaceuticals, biologics, vaccines, and medical devices has driven the demand for advanced testing platforms capable of detecting both endotoxin and non-endotoxin pyrogens. The industry is gradually transitioning from traditional animal-based methods toward modern in vitro technologies that offer faster turnaround times and improved reproducibility. For instance, in May 2025, Minerva Biolabs GmbH introduced the NAT-MAT system, a next-generation pyrogen-detection platform that integrates the Monocyte Activation Test (MAT) with digital PCR. The system measures cytokine gene expression, including IL-1β and TNF-α, enabling more sensitive and rapid detection compared to conventional ELISA-based MAT assays. Such innovations highlight the expanding scope of advanced molecular and cell-based diagnostic technologies within pharmaceutical quality control processes.
In January 2026, BETMAT Biotechnology launched high-performance sustainable endotoxin testing services designed to meet evolving quality control requirements in pharmaceutical and medical device manufacturing. The new service focuses on providing reliable bacterial endotoxin testing (BET) solutions that comply with international pharmacopeial standards while supporting sustainability initiatives in laboratory testing. The service launch reflects the growing demand for efficient, standardized, and environmentally responsible endotoxin-detection technologies in pharmaceutical manufacturing. BETMAT’s testing infrastructure incorporates advanced automated instrumentation and strict quality management systems aligned with global pharmacopeial requirements, including USP, EP, BP, and ChP, ensuring traceable and reliable results.
Furthermore, the development of integrated testing platforms is strengthening the role of automated, standardized pyrogen-detection solutions across pharmaceutical manufacturing workflows. The NAT-MAT platform includes ready-to-use macrophage cells, nucleic acid extraction kits, and a triplex digital PCR assay, enabling reliable and automated testing for both quality control and in-process monitoring. These developments reflect the growing shift toward comprehensive testing systems that can improve efficiency and reduce manual laboratory procedures.
In addition, the ability of such technologies to support complete pyrogen and endotoxin testing creates opportunities to gradually replace traditional animal-based methods, such as the Rabbit Pyrogen Test. As regulatory agencies and industry stakeholders increasingly promote animal-free testing approaches, the adoption of advanced in vitro pyrogen detection technologies is expected to expand, thereby broadening the market scope and encouraging continued innovation in endotoxin and pyrogen and endotoxin testing solutions.
Increasing investment in R&D by the government and manufacturing companies for product development is one of the major factors contributing to the market's growth. New product development and launch is a key strategy adopted by manufacturers to maintain their dominance and to get maximum revenue share in the sector. As stated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2023, the research-based pharmaceutical industry invested around USD 48.65 billion in R&D in Europe in 2022. Hence, the need for pyrogen and endotoxin testing products is anticipated to upsurge during the forecast period.
Furthermore, the pyrogen and endotoxin testing industry is driven by the increasing demand for therapeutic drugs. Several companies are actively involved in developing new drug therapies. For instance, in 2023, the FDA approved 55 new drugs. Pyrogen testing in drug development assesses the presence or absence of pyrogens in parenteral pharmaceutical products. Moreover, the sterility of any drug does not indicate that it is pyrogen-free. Therefore, drugs that are expected to be sterile must be tested for the presence of pyrogens to control febrile reactions in patients.
Global Pyrogen And Endotoxin Testing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global pyrogen and endotoxin testing market report based on product, technology, application, end-use, and region.Product Outlook (Revenue, USD Billion, 2021-2033)
- Consumables
- Limulus Amebocyte Lysate (LAL) Endotoxin Test Kits
- Chromogenic & Turbidimetric Reagents
- Recombinant Factor C (rFC) Reagents
- Monocyte Activation Test (MAT) Kits and Reagents
- Control standard endotoxins and buffers
- Endotoxin-free Lab Consumables
- Instruments
- Endotoxin Testing Systems
- Microplate and Kinetic Readers
- Automated Endotoxin Detection Systems
- Incubators and Sample Preparation Units
- Services
- Contract Endotoxin and Pyrogen and Endotoxin Testing for IVD Manufacturers
- Method Validation and Compliance Testing
- Laboratory Contamination and Quality Assurance testing
Technology Outlook (Revenue, USD Billion, 2021-2033)
- Bacterial Endotoxin Testing (BET)
- Gel Clot Method
- Chromogenic Method
- Turbidimetric Method
- Recombinant Endotoxin Detection
- Pyrogen Detection
- Monocyte Activation Test (MAT)
- Rabbit Pyrogen Test
Application Outlook (Revenue, USD Billion, 2021-2033)
- Product Safety & Batch Release Testing
- Manufacturing Process & Raw Material Control
- Validation & Regulatory Compliance Testing
- Laboratory & Clinical Environment Contamination Control
End-use Outlook (Revenue, USD Billion, 2021-2033)
- Pharmaceutical & Biopharmaceutical Companies
- Medical Device Manufacturers
- Biotechnology & Life Sciences Companies
- Contract Research & Manufacturing Organizations (CROs & CDMOs)
- Clinical & Diagnostic Laboratories
Regional Outlook (Revenue, USD Billion, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pyrogen and Endotoxin Testing Market Variables, Trends & Scope
Chapter 4. Pyrogen and Endotoxin Testing Market: Product Estimates & Trend Analysis
Chapter 5. Pyrogen and Endotoxin Testing Market: Technology Estimates & Trend Analysis
Chapter 6. Pyrogen and Endotoxin Testing Market: Application Estimates & Trend Analysis
Chapter 7. Pyrogen and Endotoxin Testing Market: End Use Estimates & Trend Analysis
Chapter 8. Pyrogen and Endotoxin Testing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Charles River Laboratories
- bioMérieux
- Associates of Cape Cod, Inc.
- FUJIFILM Wako Pure Chemical Corporation
- Bioendo Technology
- GenScript
- ACROBiosystems
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Sartorius AG
- Eurofins Scientific
- WuXi AppTec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.56 Billion |
| Forecasted Market Value ( USD | $ 4.46 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
